Acrivon Therapeutics M&A announcement
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everyone, and welcome to today's webcast. My name is Adam Levy, and I'm Chief Financial Officer and Head of Investor Relations at Acrivon Therapeutics. This afternoon, we are excited to host a key opinion leader panel to discuss our recently announced acquisition of two I&I assets, ACR-525, formerly known as AQ280, an oral JAK1 inhibitor, and a PKCθ inhibitor preclinical program. As a reminder and point of context, this acquisition represents Acrivon doing exactly what we said we would do. Specifically, I&I has long been part of our strategic narrative because of the suitability of our AI-driven AP3 platform in this space, and this deal reflects the execution on this strategy with what we believe is a highly differentiated oral JAK1 inhibitor. Next slide. I'd like to remind you that certain statements made during this call, including those made by participants in the KOL panel, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934 as amended.
Next slide, please. Here's our agenda for today. Peter will provide an introduction, and together with Mansoor, provide an overview of the I&I assets we have acquired. We will then have brief presentations led by our esteemed KOLs, who I will introduce shortly. These presentations will cover EoE unmet need, as well as current standard of care. Following the discussion, we will have a brief Q&A session. Please submit questions on the text panel you see on your screen. On the next slide, you see our esteemed KOLs, both thought leaders in eosinophilic esophagitis. Arjan Bredenoord. Dr. Bredenoord is a Professor of Gastroenterology and Hepatology at Amsterdam University Medical Center.
He's the former President of the European Society of Eosinophilic Esophagitis, EUREOS, a member of the UEG Scientific Committee. Evan Dellon. Dr. Dellon is a Professor, Department of Medicine, Division of Gastroenterology and Hepatology, and Director, Center for Esophageal Diseases and Swallowing at the School of Medicine, University of North Carolina at Chapel Hill. Joining the call today from Acrivon will be our Chief Executive Officer, President, and Co-Founder, Peter Blume-Jensen, who is the inventor of the AP3 platform, as well as our Chief Medical Officer, Mansoor Raza Mirza, who has led numerous guideline-changing studies. We also have Erick Gamelin, our Chief Development Officer, on the call. He has a distinguished career and accomplishments both in oncology and I&I, including prestigious appointments by the French Ministry of Health.
With that, I'll now turn the call over to Peter.
Thank you so much, Adam, and thank you to everyone calling in for this corporate webcast today with our expert key opinion leaders. We are super excited to share with you all today how we used our generative AI-driven AP3 platform to identify what we believe is a very differentiated, highly selective oral phase II-ready JAK inhibitor, as well as a selective preclinical PKCθ inhibitor. Next slide, please. For those of you who are new to Acrivon, we have a pioneering platform called Acrivon Predictive Precision Proteomics, or AP3 in short, which we leverage for all our precision medicine discovery and development. The platform was specifically designed to enable streamlined development to phase II clinical POC without relying on genetic alterations or any clinical information.
What you see in the middle is that the concept is based on the central dogma that instead of relying on genetic alterations and inferring from them, or for that matter, transcriptomic alterations, and infer from them how a drug might act in a diseased cell, we directly have developed tools with our generative AI to measure how a drug regulates the intracellular signaling pathways at a global level. Everything we do is drug-centric and directly enable us to match the mechanism of action with any drug of any modality, regardless disease type, with the disease-driving pathways. Acrivon actually means exact or accurate to symbolize that exact or accurate match with the drug MOA. We have a number of proprietary tools that we've developed and keep developing and expanding in that context. Next slide, please. Here's an overview of our generative AI phosphoproteomics platform.
Notably, in contrast to most AI-driven and AI-based life sciences companies, our generative learning is applied primarily to a massive amount of, on the left side, of proprietary in-house generated data. As such, we have profiled dozens and dozens of compounds, whether it's leads or hits or approved compounds, and we have all this existing in the cloud in an AP3 interactome accessible to all scientists at Acrivon. We have generated a data portal, an AP3 data portal, that converts all multimodal data from the left side, whether it's MS data or biological data or structured data, into AI-enabled or amenable data for our proprietary AI tools. They're shown in the blue periphery or ring in the middle of this figure, and you can see that it enables network mapping, pathway mapping.
We have various tools that also are specifically developed to understand at high resolution how a drug activates or inhibits signaling pathways inside a cell. This is what enables us, on the right side, to do patient responder prediction, do indication finding, identify rational drug combinations, et cetera, before we enter the clinic. Today, as you can see highlighted in bold, we have used our platform to prioritize an asset that is a highly selective JAK1 inhibitor, and we have also mapped all the global PD effects of that drug and identified both a sensitive indication as well as rational drug combinations for this asset. Next slide. Here, we'll hand it over to our Chief Medical Officer, Mansoor Mirza.
Mansoor, please. Thank you. Thank you, Peter.
Here you see our updated pipeline, now incorporating our I&I franchise. We remain on track for our pre-specified interim analysis of ACR-368 trial and will not discuss that further today. We recently updated on the exciting activity of our first-in-class WEE1/PKMYT1 inhibitor, ACR-2316, in AP3 predictive tumor types, including endometrial and lung cancer. I am very excited about the ongoing clinical benefit, now over 65 weeks in heavily pre-treated lung cancer patients, as well as a confirmed CR in squamous lung cancer. I encourage you all to join the late-breaking oral plenary presentation on ACR-2316 by Dr. Tim Yap at the upcoming Triple Meeting in Barcelona. We also recently updated on our potentially first-in-class CDK11 inhibitor development candidate, ACR-7280, which has shown complete regression in preclinical AML in vivo models, also on an AP3 predicted sensitive tumor type.
Today, focus will be entirely on our new I&I programs, identified using our AI-driven AP3 platform as highly differentiated based on head-to-head profiling against approved JAK inhibitors and dupilumab. Next slide, please. As Peter mentioned, it is our AI-driven AP3 platform that enabled us to identify this exciting asset. You will see on the next slides how we profiled it extensively head-to-head against other approved JAK inhibitors and dupilumab, and found it to have highly differentiated, attractive features and desirable global pathway effects. It shows a highly JAK1 selective profile and orally available. Very importantly, it has desirable suppression of non-SMAD TGF-beta signaling. Many inflammatory disorders also lead to fibrosis, so obviously, this could be potentially of additional benefit.
Moreover, in contrast to a couple of other JAK inhibitors, we do not see any obvious activation of pro-apoptotic BAD signaling, which could be a potential safety advantage and which has been linked to rhabdomyolysis for some JAK inhibitors. Finally, we noticed, based on our AP3 profiling, broader anti-inflammatory effects beyond IL-4 and IL-13 signaling pathways, which are inhibited by dupilumab. Our phase I data were very encouraging. We saw dose-dependent PD effects in preclinical models, as well as a dose-dependent reduction of the inflammation marker CXCL10, and dose-proportional predictable PK in phase I, supporting once-daily oral dosing. Consistent with high selectivity of ACR-525, initial phase I safety was very favorable. Based on these data, ACR-525 is now phase II ready, and our initial target indication is eosinophilic esophagitis.
We, of course, also see a broader I&I opportunity, both as a single agent as well as in combination, given the high JAK1 selectivity and oral availability. Based on AP3, we see opportunity to combine with other agents, like our acquired preclinical selective PKCθ inhibitor, as well as IL-23 inhibitors and TNF antagonists. Importantly, the asset is wholly owned with no milestone or royalty obligations, and there is extension opportunity beyond the composition of matter expiration of 2038. Peter. Peter, would you take next slide, please?
Thank you so much, Mansoor. As we mentioned, it is really the AI-driven AP3 platform that uniquely enabled us to identify this as a very attractive JAK1 selective inhibitor. What we did here is outlined here. We profiled this asset head-to-head against approved JAK inhibitors, mentioned here, as well as dupilumab, the IL-4, IL-13 directed antibody. Based on that, we were able to, in different disease-relevant cellular models, both interferon-alpha stimulated and Th2 polarized cells using IL-4 and T-cell receptor activation, we were able to uncover the drug-regulated pathway mechanisms using our mass spec-based AP3 phosphoproteomic profiling. On the right-hand side, you can just see an example of what you can see with this unbiased approach.
We saw a very, very dramatic reduction of a lot of the key or core cytokine-related regulated pathways, including primarily, as you can see, the size of the dot here implies the magnitude of the effect. Blue is downregulation, not of levels, but of activity, and red is upregulation. You can see the most dramatic downregulation was actually identified for the very important pathways driven by IL-4 and IL-13. We also could directly, out of our over 100,000 quantified mapped phosphorylation sites, we can go in and directly pull out the downregulation of, for example, phospho-STAT6, a key readout of these pathways. You can see the dose-dependent reduction of that compared to IL-4 stimulated control cells.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
